Free tool
FAERS Monitor: Impavido
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204684 or its brand name (Impavido, Miltefosine). Reports on generic versions are filed under their own applications.
Reports
388
Serious
377
97% of reports
Hospitalization
133
Death reported
121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use122
- drug ineffective109
- nausea59
- drug ineffective for unapproved indication57
- condition aggravated33
- vomiting33
- product use in unapproved indication26
- disease recurrence24
- decreased appetite22
- visceral leishmaniasis20
- renal failure18
- acute kidney injury17
- toxicity to various agents16
- acanthamoeba infection15
- gastrointestinal disorder15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2013 | 4 |
| 2014 | 16 |
| 2015 | 11 |
| 2016 | 8 |
| 2017 | 23 |
| 2018 | 29 |
| 2019 | 31 |
| 2020 | 32 |
| 2021 | 46 |
| 2022 | 27 |
| 2023 | 31 |
| 2024 | 32 |
| 2025 | 58 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acanthamoeba infectionSignal | 15 | 4704.8 | 2802.5 | 60,658 |
| visceral leishmaniasisSignal | 20 | 1545.9 | 1002.4 | 28,541 |
| drug ineffective for unapproved indicationSignal | 57 | 56.4 | 44.3 | 3,049 |
| disease recurrenceSignal | 24 | 27.4 | 18.6 | 584 |
| gastrointestinal disorderSignal | 15 | 9.1 | 5.5 | 100 |
| off label useSignal | 122 | 7.6 | 6.5 | 717 |
| renal failureSignal | 18 | 7.3 | 4.7 | 93 |
| acute kidney injurySignal | 17 | 6.0 | 3.8 | 67 |
| condition aggravatedSignal | 33 | 5.9 | 4.2 | 131 |
| product use in unapproved indicationSignal | 26 | 5.7 | 3.9 | 97 |
| toxicity to various agentsSignal | 16 | 5.1 | 3.2 | 50 |
| decreased appetiteSignal | 22 | 5.1 | 3.4 | 70 |
| drug ineffectiveSignal | 109 | 4.5 | 3.8 | 311 |
| nauseaSignal | 59 | 4.0 | 3.2 | 137 |
| vomitingSignal | 33 | 3.8 | 2.7 | 67 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.